ID | 63232 |
FullText URL | |
Author |
Ueno, Sayaka
Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sudo, Tamotsu
Section of Translational Research, Hyogo Cancer Center
Hirasawa, Akira
Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
researchmap
|
Abstract | Ataxia-telangiectasia mutated (ATM) functions as a key initiator and coordinator of DNA damage and cellular stress responses. ATM signaling pathways contain many downstream targets that regulate multiple important cellular processes, including DNA damage repair, apoptosis, cell cycle arrest, oxidative sensing, and proliferation. Over the past few decades, associations between germline ATM pathogenic variants and cancer risk have been reported, particularly for breast and pancreatic cancers. In addition, given that ATM plays a critical role in repairing double-strand breaks, inhibiting other DNA repair pathways could be a synthetic lethal approach. Based on this rationale, several DNA damage response inhibitors are currently being tested in ATM-deficient cancers. In this review, we discuss the current knowledge related to the structure of the ATM gene, function of ATM kinase, clinical significance of ATM germline pathogenic variants in patients with hereditary cancers, and ongoing efforts to target ATM for the benefit of cancer patients.
|
Keywords | hereditary tumors
ATM
DNA damage
redox homeostasis
tumor profiling
precision therapy
|
Published Date | 2022-01-04
|
Publication Title |
International Journal Of Molecular Sciences
|
Volume | volume23
|
Issue | issue1
|
Publisher | MDPI
|
Start Page | 523
|
ISSN | 1422-0067
|
NCID | AA12038549
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © 2022 by the authors.
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.3390/ijms23010523
|
License | https://creativecommons.org/licenses/by/4.0/
|